News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
605,319 Results
Type
Article (43423)
Company Profile (320)
Press Release (561575)
Multimedia
Podcasts (81)
Webinars (13)
Section
Business (168121)
Career Advice (2450)
Deals (30404)
Drug Delivery (108)
Drug Development (78918)
Employer Resources (148)
FDA (14514)
Job Trends (13035)
News (296848)
Policy (28633)
Tag
Academia (2682)
Academic (1)
Accelerated approval (10)
Adcomms (29)
Allergies (98)
Alliances (43133)
ALS (117)
Alzheimer's disease (1515)
Antibody-drug conjugate (ADC) (175)
Approvals (14494)
Artificial intelligence (315)
Autoimmune disease (34)
Automation (18)
Bankruptcy (327)
Best Places to Work (10684)
BIOSECURE Act (16)
Biosimilars (112)
Biotechnology (259)
Bladder cancer (97)
Brain cancer (37)
Breast cancer (373)
Cancer (2928)
Cardiovascular disease (232)
Career advice (2063)
Career pathing (32)
CAR-T (195)
CDC (28)
Cell therapy (524)
Cervical cancer (21)
Clinical research (64832)
Collaboration (1021)
Company closure (3)
Compensation (504)
Complete response letters (29)
COVID-19 (2604)
CRISPR (67)
C-suite (353)
Cystic fibrosis (115)
Data (3025)
Decentralized trials (2)
Denatured (16)
Depression (74)
Diabetes (346)
Diagnostics (5893)
Digital health (19)
Diversity (5)
Diversity, equity & inclusion (41)
Drug discovery (143)
Drug pricing (124)
Drug shortages (25)
Duchenne muscular dystrophy (135)
Earnings (62680)
Editorial (43)
Employer branding (20)
Employer resources (137)
Events (91386)
Executive appointments (881)
FDA (16122)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (917)
Gene editing (142)
Generative AI (24)
Gene therapy (412)
GLP-1 (819)
Government (4344)
Grass and pollen (5)
Guidances (178)
Healthcare (17293)
HIV (41)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (173)
Immuno-oncology (9)
Indications (39)
Infectious disease (2782)
Inflammatory bowel disease (160)
Inflation Reduction Act (13)
Influenza (66)
Intellectual property (122)
Interviews (524)
IPO (14341)
IRA (49)
Job creations (2763)
Job search strategy (1685)
Kidney cancer (15)
Labor market (34)
Layoffs (492)
Leadership (26)
Legal (6093)
Liver cancer (80)
Longevity (10)
Lung cancer (420)
Lymphoma (205)
Machine learning (11)
Management (52)
Manufacturing (366)
MASH (99)
Medical device (11215)
Medtech (11219)
Mergers & acquisitions (16751)
Metabolic disorders (874)
Multiple sclerosis (97)
NASH (23)
Neurodegenerative disease (131)
Neuropsychiatric disorders (42)
Neuroscience (2236)
NextGen: Class of 2025 (5975)
Non-profit (4129)
Now hiring (43)
Obesity (435)
Opinion (250)
Ovarian cancer (101)
Pain (111)
Pancreatic cancer (120)
Parkinson's disease (193)
Partnered (21)
Patents (300)
Patient recruitment (165)
Peanut (52)
People (54710)
Pharmaceutical (55)
Pharmacy benefit managers (16)
Phase I (20362)
Phase II (28638)
Phase III (21307)
Pipeline (1644)
Policy (203)
Postmarket research (2391)
Preclinical (8641)
Press Release (60)
Prostate cancer (142)
Psychedelics (45)
Radiopharmaceuticals (266)
Rare diseases (502)
Real estate (4512)
Recruiting (61)
Regulatory (20707)
Reports (29)
Research institute (2286)
Resumes & cover letters (360)
Rett syndrome (10)
RNA editing (10)
RSV (46)
Schizophrenia (95)
Series A (158)
Series B (110)
Service/supplier (3)
Sickle cell disease (64)
Special edition (16)
Spinal muscular atrophy (154)
Sponsored (31)
Startups (3198)
State (2)
Stomach cancer (15)
Supply chain (67)
Tariffs (49)
The Weekly (64)
Vaccines (762)
Venture capital (54)
Weight loss (277)
Women's health (38)
Worklife (17)
Date
Today (75)
Last 7 days (328)
Last 30 days (1729)
Last 365 days (29863)
2025 (16236)
2024 (33635)
2023 (37498)
2022 (48412)
2021 (52024)
2020 (50008)
2019 (42544)
2018 (32073)
2017 (29661)
2016 (28191)
2015 (32973)
2014 (25388)
2013 (20574)
2012 (21779)
2011 (22687)
2010 (20427)
Location
Africa (744)
Alabama (65)
Alaska (4)
Arizona (180)
Arkansas (12)
Asia (36816)
Australia (7278)
California (6964)
Canada (2282)
China (665)
Colorado (300)
Connecticut (281)
Delaware (190)
Europe (82669)
Florida (1048)
Georgia (226)
Hawaii (1)
Idaho (57)
Illinois (590)
India (26)
Indiana (318)
Iowa (15)
Japan (227)
Kansas (99)
Kentucky (26)
Louisiana (14)
Maine (53)
Maryland (973)
Massachusetts (5180)
Michigan (229)
Minnesota (399)
Mississippi (3)
Missouri (87)
Montana (24)
Nebraska (22)
Nevada (74)
New Hampshire (68)
New Jersey (1998)
New Mexico (25)
New York (1958)
North Carolina (1031)
North Dakota (7)
Northern California (3015)
Ohio (209)
Oklahoma (12)
Oregon (33)
Pennsylvania (1470)
Puerto Rico (17)
Rhode Island (33)
South America (1017)
South Carolina (31)
South Dakota (1)
Southern California (2673)
Tennessee (111)
Texas (1045)
United States (25728)
Utah (213)
Virginia (171)
Washington D.C. (65)
Washington State (601)
West Virginia (4)
Wisconsin (62)
605,319 Results for "calliditas therapeutics formerly known as pharmalink".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Calliditas Therapeutics Presented at the 62nd European Renal Association Congress
June 10, 2025
·
3 min read
Calliditas Therapeutics to Attend Conferences in April
Calliditas Therapeutics AB today announced that its management will be attending the following upcoming investor and industry conferences.
April 9, 2024
·
1 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Deals
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas.
May 28, 2024
·
7 min read
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Calliditas Therapeutics AB today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO ® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN).
May 28, 2024
·
8 min read
Deals
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.
May 28, 2024
·
24 min read
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Calliditas Therapeutics AB today announced upcoming data presentations and a sponsored symposium at the 61st European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 - 26, 2024.
May 15, 2024
·
6 min read
Business
Calliditas Therapeutics’ 2023 Annual Report Published
Calliditas Therapeutics AB, announces that the Annual Report for 2023 now is available at the company’s website.
April 24, 2024
·
3 min read
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology’s World Congress of Nephrology.
April 8, 2024
·
8 min read
Deals
Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics
The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.
May 28, 2024
·
2 min read
·
Tyler Patchen
1 of 60,532
Next
